2024-09-23 - Analysis Report
## Gilead Sciences Inc (GILD) Stock Analysis Report

**Company Overview:** Gilead Sciences Inc is a biopharmaceutical company that researches, develops, and commercializes life-saving drugs for patients with life-threatening diseases.

**Performance Analysis:**

**1. Performance vs. S&P 500:**

* GILD's cumulative return is -12.88%, significantly underperforming the S&P 500 (VOO) which has a cumulative return of 132.53%. 
* This difference results in a significant underperformance compared to the S&P 500, with a relative underperformance of 6.43% (based on historical data). This means GILD has underperformed the S&P 500 by a magnitude that falls within the 6.43% percentile of historical underperformance. 

**2. Recent Price Movements:**

* GILD's closing price is $83.94.
* The stock is currently trading above its 5-day, 20-day, and 60-day moving averages, indicating potential upward momentum.
* **5-day moving average:** $83.69
* **20-day moving average:** $80.50
* **60-day moving average:** $75.35

**3. Technical Indicators:**

* **RSI (76.22):** This indicates that GILD is currently in overbought territory, which suggests potential for a short-term correction.
* **PPO (0.25):** A positive PPO reading indicates that the price momentum is bullish, further supporting the potential for a near-term upward move.
* **Delta_Previous_Relative_Divergence (1.13):** A positive value indicates that the stock is currently experiencing a bullish divergence, further supporting the potential for an upward move.
* **Expected Return (18.37%):** This represents the maximum expected return over a 5-year period based on current investment, suggesting potential for long-term growth.

**4. Recent Earnings and Outlook:**

* Gilead Sciences has experienced mixed recent earnings performance with both positive and negative EPS results over the past few quarters.
* **Recent Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

* While the most recent earnings report shows an improvement, the company's overall performance is still volatile. Investors need to monitor future earnings releases and the market's reaction to gain further insight into the company's growth trajectory.

**5. Summary:**

* GILD has significantly underperformed the S&P 500 in the past, but recent price action and technical indicators suggest potential for a short-term upward move.
* However, the stock is currently in overbought territory and the company's earnings performance remains volatile, suggesting potential for a near-term correction. 
* Long-term investors may find GILD attractive due to its strong expected return potential. 

**6. Conclusion:**

While Gilead Sciences shows signs of potential short-term upward momentum, the current overbought conditions and volatility in earnings performance suggest investors should proceed with caution. Long-term investors may find the company's potential for long-term growth attractive, but short-term investors should consider the risk of a near-term correction.  Further analysis is required before making any investment decisions.
